{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T13:34:03Z","timestamp":1793453643922,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009102","name":"Education Department of Jiangxi Province","doi-asserted-by":"publisher","award":["GJJ2400104"],"award-info":[{"award-number":["GJJ2400104"]}],"id":[{"id":"10.13039\/501100009102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018530","name":"Major Science and Technology Projects in Anhui Province","doi-asserted-by":"publisher","award":["20213AAG01013"],"award-info":[{"award-number":["20213AAG01013"]}],"id":[{"id":"10.13039\/501100018530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004637","name":"Nanchang University","doi-asserted-by":"publisher","award":["YFYPY2023103"],"award-info":[{"award-number":["YFYPY2023103"]}],"id":[{"id":"10.13039\/501100004637","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005891","name":"State Administration of Traditional Chinese Medicine of the People's Republic of China","doi-asserted-by":"publisher","award":["2024A0090"],"award-info":[{"award-number":["2024A0090"]}],"id":[{"id":"10.13039\/501100005891","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32571510"],"award-info":[{"award-number":["32571510"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472225"],"award-info":[{"award-number":["82472225"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20232BAB206047"],"award-info":[{"award-number":["20232BAB206047"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20242BAB20404"],"award-info":[{"award-number":["20242BAB20404"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20252BAC240624"],"award-info":[{"award-number":["20252BAC240624"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020205","name":"Health Commission of Jiangxi Province","doi-asserted-by":"publisher","award":["202610030"],"award-info":[{"award-number":["202610030"]}],"id":[{"id":"10.13039\/501100020205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012420","name":"5511 Science and Technology Innovation Talent Project of Jiangxi Province","doi-asserted-by":"publisher","award":["jxsq2023201037"],"award-info":[{"award-number":["jxsq2023201037"]}],"id":[{"id":"10.13039\/501100012420","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Materials Today Bio"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.mtbio.2026.103679","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:53:24Z","timestamp":1789628004000},"page":"103679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting an ASCL1\u2013WNT11\u2013ERK feed-forward loop to overcome pyrotinib resistance in HER2-positive breast cancer"],"prefix":"10.1016","volume":"41","author":[{"given":"Fang","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boxuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingliang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zide","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanglin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9595-7945","authenticated-orcid":false,"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocheng","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianmei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linwei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengqi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1057-1695","authenticated-orcid":false,"given":"Aiping","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mtbio.2026.103679_bib1","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.mtbio.2026.103679_bib2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.mtbio.2026.103679_bib3","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41571-024-00939-2","article-title":"Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance","volume":"21","author":"Waks","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.mtbio.2026.103679_bib4","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1200\/JCO.2016.69.6179","article-title":"Phase I study and biomarker analysis of pyrotinib, a novel irreversible Pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-Positive metastatic breast cancer","volume":"35","author":"Ma","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.mtbio.2026.103679_bib5","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12916-023-02999-0","article-title":"Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial","volume":"21","author":"Cao","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.mtbio.2026.103679_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-087259","article-title":"Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial","volume":"392","author":"Ma","year":"2026","journal-title":"BMJ"},{"key":"10.1016\/j.mtbio.2026.103679_bib7","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1038\/s41467-020-19704-x","article-title":"EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy","volume":"11","author":"Bao","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103679_bib8","doi-asserted-by":"crossref","first-page":"6667","DOI":"10.1038\/s41467-021-27093-y","article-title":"HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway","volume":"12","author":"Smith","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103679_bib9","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/s41467-022-30217-7","article-title":"N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer","volume":"13","author":"Zou","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103679_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12156","article-title":"ERR\u03b1 mediates metabolic adaptations driving lapatinib resistance in breast cancer","volume":"7","author":"Deblois","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103679_bib11","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-20-1265","article-title":"Ontogeny and vulnerabilities of drug-tolerant persisters in HER2+ breast cancer","volume":"12","author":"Chang","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.mtbio.2026.103679_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2023.100913","article-title":"P110\u03b1 inhibitor alpelisib exhibits a synergistic effect with pyrotinib and reverses pyrotinib resistant in HER2+ breast cancer","volume":"43","author":"Chen","year":"2023","journal-title":"Neoplasia"},{"key":"10.1016\/j.mtbio.2026.103679_bib13","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.7150\/ijbs.99275","article-title":"PPARG activation of Fatty acid metabolism drives resistance to Anti-HER2 therapies in HER2-Positive breast cancer","volume":"21","author":"Xiong","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.mtbio.2026.103679_bib14","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.celrep.2016.06.081","article-title":"ASCL1 and NEUROD1 reveal heterogeneity in pulmonary neuroendocrine tumors and regulate distinct genetic programs","volume":"16","author":"Borromeo","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.mtbio.2026.103679_bib15","doi-asserted-by":"crossref","first-page":"14788","DOI":"10.1073\/pnas.1410419111","article-title":"ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers","volume":"111","author":"Augustyn","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.mtbio.2026.103679_bib16","article-title":"Identification of molecular subtypes based on chromatin regulator-related genes and experimental verification of the role of ASCL1 in conferring chemotherapy resistance to breast cancer","volume":"15","author":"Li","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mtbio.2026.103679_bib17","article-title":"An integrative analysis of ASCL1 in breast cancer and inhibition of ASCL1 increases paclitaxel sensitivity by activating ferroptosis via the CREB1\/GPX4 axis","volume":"16","author":"Yang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mtbio.2026.103679_bib18","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/s41374-019-0277-y","article-title":"Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology","volume":"99","author":"Tenjin","year":"2019","journal-title":"Lab. Invest."},{"key":"10.1016\/j.mtbio.2026.103679_bib19","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/s13046-021-02187-z","article-title":"WNT11\/ROR2 signaling is associated with tumor invasion and poor survival in breast cancer","volume":"40","author":"Menck","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.mtbio.2026.103679_bib20","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41573-021-00199-0","article-title":"Advances in targeting 'undruggable' transcription factors with small molecules","volume":"20","author":"Henley","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.mtbio.2026.103679_bib21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41573-024-00912-9","article-title":"RNAi-based drug design: considerations and future directions","volume":"23","author":"Tang","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.mtbio.2026.103679_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202403701","article-title":"Ionizable drugs enable intracellular delivery of Co-Formulated siRNA","volume":"36","author":"Slaughter","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.mtbio.2026.103679_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz6108","article-title":"Targeted gene silencing in vivo by platelet membrane-coated metal-organic framework nanoparticles","volume":"6","author":"Zhuang","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.mtbio.2026.103679_bib24","doi-asserted-by":"crossref","first-page":"33070","DOI":"10.1021\/acsami.8b13393","article-title":"In situ synthesis of ultrathin ZIF-8 film-coated MSNs for codelivering Bcl-2 siRNA and Doxorubicin to enhance chemotherapeutic efficacy in drug-resistant cancer cells","volume":"10","author":"Pan","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.mtbio.2026.103679_bib25","doi-asserted-by":"crossref","first-page":"21587","DOI":"10.1021\/acsanm.3c03564","article-title":"Aptamer-Functionalized ZIF-8 nanomedicine for targeted delivery of gefitinib and siRNA to treat tyrosine-kinase-inhibitor-resistant nonsmall-cell lung cancer","volume":"6","author":"Liu","year":"2023","journal-title":"ACS Appl. Nano Mater."},{"key":"10.1016\/j.mtbio.2026.103679_bib26","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.biomaterials.2018.08.022","article-title":"The effect of surface poly(ethylene glycol) length on in vivo drug delivery behaviors of polymeric nanoparticles","volume":"182","author":"Wang","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.mtbio.2026.103679_bib27","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1479-5876-10-148","article-title":"Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro","volume":"10","author":"Liu","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.mtbio.2026.103679_bib28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.mtbio.2026.103679_bib29","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s10549-009-0674-9","article-title":"An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients","volume":"123","author":"Gy\u00f6rffy","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.mtbio.2026.103679_bib30","doi-asserted-by":"crossref","first-page":"D165","DOI":"10.1093\/nar\/gkab1113","article-title":"Jaspar 2022: the 9th release of the open-access database of transcription factor binding profiles","volume":"50","author":"Castro-Mondragon","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.mtbio.2026.103679_bib31","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrm3470","article-title":"The complex world of WNT receptor signalling","volume":"13","author":"Niehrs","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.mtbio.2026.103679_bib32","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3390\/cells10010142","article-title":"The WNT\/ROR pathway in cancer: from signaling to therapeutic intervention","volume":"10","author":"Menck","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.mtbio.2026.103679_bib33","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/sj.cgt.7701012","article-title":"A novel MASH1 enhancer with N-myc and CREB-binding sites is active in neuroblastoma","volume":"14","author":"Watt","year":"2007","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.mtbio.2026.103679_bib34","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.273.5277.959","article-title":"Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase","volume":"273","author":"Xing","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.mtbio.2026.103679_bib35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13058-023-01694-5","article-title":"Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now","volume":"25","author":"Qi","year":"2023","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.mtbio.2026.103679_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176725","article-title":"Mechanisms of acquired resistance to HER2-Positive breast cancer therapies induced by HER3: a comprehensive review","volume":"977","author":"Geng","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.mtbio.2026.103679_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004652","article-title":"Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer","volume":"6","author":"Niederst","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.mtbio.2026.103679_bib38","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.humpath.2022.06.003","article-title":"Expression of novel neuroendocrine markers in breast carcinomas: a study of INSM1, ASCL1, and POU2F3","volume":"127","author":"Zhong","year":"2022","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.mtbio.2026.103679_bib39","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00428-012-1223-1","article-title":"Human achaete-scute homolog-1 expression in neuroendocrine breast carcinoma","volume":"460","author":"Righi","year":"2012","journal-title":"Virchows Arch."},{"key":"10.1016\/j.mtbio.2026.103679_bib40","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1038\/s44321-024-00088-0","article-title":"DUSP6 inhibition overcomes neuregulin\/HER3-driven therapy tolerance in HER2+ breast cancer","volume":"16","author":"Momeny","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.mtbio.2026.103679_bib41","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3389\/fimmu.2018.02490","article-title":"Novel antibody drug conjugates targeting tumor-associated receptor tyrosine kinase ROR2 by functional screening of fully human antibody libraries using Transpo-mAb display on progenitor B cells","volume":"9","author":"Hellmann","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mtbio.2026.103679_bib42","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2490078","article-title":"Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody-drug conjugate","volume":"17","author":"Chang","year":"2025","journal-title":"mAbs"},{"key":"10.1016\/j.mtbio.2026.103679_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.111589","article-title":"Targeting ROR2 homooligomerization disrupts ROR2-dependent signaling and suppresses stem-like cell properties of human breast adenocarcinoma","volume":"28","author":"Leng","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.mtbio.2026.103679_bib44","doi-asserted-by":"crossref","first-page":"37600","DOI":"10.1039\/D0RA07950B","article-title":"Synthesis and modification of ZIF-8 and its application in drug delivery and tumor therapy","volume":"10","author":"Wang","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.mtbio.2026.103679_bib45","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.3390\/cancers14163935","article-title":"Nanoscale Zeolitic Imidazolate Framework (ZIF)-8 in cancer theranostics: current challenges and prospects","volume":"14","author":"Xie","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.mtbio.2026.103679_bib46","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12951-022-01255-6","article-title":"IR792-MCN@ZIF-8-PD-L1 siRNA drug delivery system enhances photothermal immunotherapy for triple-negative breast cancer under near-infrared laser irradiation","volume":"20","author":"Wang","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.mtbio.2026.103679_bib47","article-title":"Automatic metabolism modulator for glycolytic intervention-induced cascade cancer therapy","volume":"3","author":"Zheng","year":"2025","journal-title":"BMEMat"},{"key":"10.1016\/j.mtbio.2026.103679_bib48","doi-asserted-by":"crossref","first-page":"18419","DOI":"10.1021\/jacs.2c06877","article-title":"Engineering Poly(ethylene glycol) nanoparticles for accelerated blood clearance inhibition and targeted drug delivery","volume":"144","author":"Tian","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.mtbio.2026.103679_bib49","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/cbdd.14143","article-title":"Aptamer-siRNA chimeras: promising tools for targeting HER2 signaling in cancer","volume":"101","author":"Dhanya","year":"2023","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.mtbio.2026.103679_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2023.125380","article-title":"Preparation and biological evaluation of antibody targeted metal-organic framework drug delivery system (TDDS) in Her2 receptor-positive cells","volume":"269","author":"Chen","year":"2024","journal-title":"Talanta"},{"key":"10.1016\/j.mtbio.2026.103679_bib51","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.actbio.2015.01.002","article-title":"Specific aptamer-conjugated mesoporous silica-carbon nanoparticles for HER2-targeted chemo-photothermal combined therapy","volume":"16","author":"Wang","year":"2015","journal-title":"Acta Biomater."},{"key":"10.1016\/j.mtbio.2026.103679_bib52","article-title":"Targeted nanoparticle for Co-delivery of HER2 siRNA and a taxane to mirror the standard treatment of HER2+ breast cancer: efficacy in breast tumor and brain metastasis","volume":"18","author":"Ngamcherdtrakul","year":"2022","journal-title":"Small"},{"key":"10.1016\/j.mtbio.2026.103679_bib53","article-title":"A multifunctional bimetallic nanoplatform for synergic local hyperthermia and chemotherapy targeting HER2-Positive breast cancer","volume":"11","author":"Zhao","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.mtbio.2026.103679_bib54","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.addr.2021.03.018","article-title":"The past, present, and future of breast cancer models for nanomedicine development","volume":"173","author":"Boix-Montesinos","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.mtbio.2026.103679_bib55","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1186\/1471-2407-12-579","article-title":"Blood vessel hyperpermeability and pathophysiology in human tumour xenograft models of breast cancer: a comparison of ectopic and orthotopic tumours","volume":"12","author":"Ho","year":"2012","journal-title":"BMC Cancer"}],"container-title":["Materials Today Bio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590006426009245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590006426009245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T13:02:37Z","timestamp":1793451757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590006426009245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":55,"alternative-id":["S2590006426009245"],"URL":"https:\/\/doi.org\/10.1016\/j.mtbio.2026.103679","relation":{},"ISSN":["2590-0064"],"issn-type":[{"value":"2590-0064","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting an ASCL1\u2013WNT11\u2013ERK feed-forward loop to overcome pyrotinib resistance in HER2-positive breast cancer","name":"articletitle","label":"Article Title"},{"value":"Materials Today Bio","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mtbio.2026.103679","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103679"}}